ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / ABT / earnings
NVO (57) PFE (73) VRTX (80) BMY (63) ⌘ Pro Terminal →

Abbott Laboratories (ABT) Next Earnings Date & Expected ±5.5% Move

$106.20 +1.56% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $106.75

Abbott Laboratories (ABT) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (56% profit margin, 12% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate) →
ROARABLE B+ • BUY Cap $180.95B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Abbott Laboratories (NYSE: ABT) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $106.20 (+1.56% 1D, market cap $180.95B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, ABT ranks #24 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABT compare to NVO and PFE in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABT carries a Roarable B+ (77/100 RQD), trailing P/E of 27.7x, gross margin of 56.4%, and ROIC of 11.9%. By comparison, NVO (Novo Nordisk A/S) holds a D+ grade (57/100 RQD, P/E 32.8x, ROIC 9.9%, cap $173.31B) and PFE (Pfizer Inc.) posts a B grade (73/100 RQD, P/E 22.0x, ROIC 5.1%, cap $170.71B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABT?
▼

Per ABT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000001800), Abbott Laboratories generated $44.33B in revenue (+5.7% YoY), $6.52B in net income, and $7.39B in free cash flow against $86.71B in total assets and $9.90B in total debt. Key quantitative strengths: Strong cash generator (56% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $106.75 (+0.52%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 16.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B+
025507510077
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B+
Cash (16)Whales (15)SEC (16)Macro (16)CEO (14)
Each axis scored 0–20
12M PRICE TARGET CONE+8.5% Base Target
$139 Bull$115 Base$87 Bear
📬 FREE ABT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABT)Realized 20D OHLCV Swing Band: ±5.5%
Deterministic 5-Pillar Attribution (77/100 Composite)
🔍 WHY ABT SCORES 77/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 16.7% FCF Margin ($7.39B FCF) & 56.4% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (21% of score)

Altman Z-Score 4.36 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution14/20 pts (-6 pt drag)

Cannibal Buyback (-1.80% YoY Shares) & executive Form 4 sales trim 6 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
69
Grade B-$102.61-0.2% Next Q
Q2 (-2Q)
72
Grade B$102.45+0.6% Next Q
Q3 (-1Q)
74
Grade B+$103.10+3% Next Q
Current
77
Grade B+$106.20+7.8% Hist 90D α
Trajectory: B- (69) → B+ (77)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ABT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 77/100 (B+) score, ABT faces multiple-compression risk if 27.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 53.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($103.86) or 200D SMA ($101.51) invalidates the momentum regime and cuts Target Base ($115.28) toward Bear Floor ($87.08).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 77%NO 23%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±5.5% Swing Band

±$5.84 Expected Swing
$100.36 (-5.5%)Spot $106.20$112.04 (+5.5%)
MODEL EARNINGS SETUP GAUGE

ABT Quantitative Pre-Earnings Setup: 77/100

Trailing EPS: $3.77 • YoY Revenue Growth: 5.7%

Model Bullish Setup (77/100)Model Risk Weight (23/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$44.33B$6.52B$7.39B56.4%
FY 20242024-12-31$41.95B$13.40B$6.35B55.4%
FY 20232023-12-31$40.11B$5.72B$5.46B56.4%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating ABT & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on ABT
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ABT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.32%⚡ TESTING RESISTANCE
2026-11-02O $102.6H $106.2L $102.6C $106.2VOL 7.29M
RES: $106.8SUP: $97.94SMA50: $103.9SMA200: $101.5
$123.1$111.9$100.8$89.65$78.51RES $106.8SUP $97.94$106.22026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABT Butterfly Map → + Track ABT →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
21.2%/yr Implied 5Y Growth

vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ABT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABT)

Health Care Rank #24 of 1016 ⚔️ NVO vs ABT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABT vs. NVO, PFE, VRTX, BMY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Abbott Laboratories (ABT) ranks #24 by composite RQD confidence (77/100, grade B+) and #11 by equity capitalization ($180.95B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. VRTX currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with ABT at 77/100 (B+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ABT ACTIVE
Abbott Laboratories
B+ 77/100 27.7x 56.4% 11.9% +1.56% $180.95B Benchmark Subject
NVO
Novo Nordisk A/S
D+ 57/100 32.8x — 9.9% +2.20% $173.31B /nvo-vs-abt →
PFE
Pfizer Inc.
B 73/100 22.0x 74.3% 5.1% +1.90% $170.71B /pfe-vs-abt →
VRTX
Vertex Pharmaceuticals Incorporated
B+ 80/100 34.6x 86.2% 20.0% +3.50% $136.87B /vrtx-vs-abt →
BMY
Bristol-Myers Squibb Company
C 63/100 17.8x 71.1% 13.3% +1.78% $125.40B /bmy-vs-abt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000001800

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Abbott Laboratories (ABT) reported GAAP revenue of $44.33B (+5.7% vs. FY2024 revenue of $41.95B , and +10.5% cumulative change since FY2023) , GAAP net income of $6.52B, operating cash flow of $9.57B, and free cash flow of $7.39B (+16.4% YoY). On the balance sheet, ABT closed FY2025 with $86.71B in total assets against $9.90B in total debt (Altman Z-Score: 4.36, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $44.33B $6.52B $9.57B $7.39B $86.71B $9.90B
FY2024 (FY) 2024-12-31 $41.95B $13.40B $8.56B $6.35B $81.41B $12.63B
FY2023 (FY) 2023-12-31 $40.11B $5.72B $7.26B $5.46B $99.52B $23.29B

3. ABT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Abbott Laboratories (NYSE: ABT) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $106.20 (+1.56% 1D, market cap $180.95B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, ABT ranks #24 in composite RQD confidence.

How does ABT compare to NVO and PFE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABT carries a Roarable B+ (77/100 RQD), trailing P/E of 27.7x, gross margin of 56.4%, and ROIC of 11.9%. By comparison, NVO (Novo Nordisk A/S) holds a D+ grade (57/100 RQD, P/E 32.8x, ROIC 9.9%, cap $173.31B) and PFE (Pfizer Inc.) posts a B grade (73/100 RQD, P/E 22.0x, ROIC 5.1%, cap $170.71B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ABT?

Per ABT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000001800), Abbott Laboratories generated $44.33B in revenue (+5.7% YoY), $6.52B in net income, and $7.39B in free cash flow against $86.71B in total assets and $9.90B in total debt. Key quantitative strengths: Strong cash generator (56% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ABT trading relative to its 50-day, 200-day, and 52-week technical levels?

ABT last traded at $106.20 (+1.56% on volume of 8,440,815 shares), positioning the stock +2.25% above its 50-day simple moving average ($103.86) and +4.62% above its 200-day simple moving average ($101.51). Across its 52-week range of $81.97 to $132.03, ABT sits at the 48.4% percentile with a 14-day RSI of 54.2 (NEUTRAL RANGE) and an implied next-earnings move of ±5.5% ($100.36 to $112.04).

ABT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ABT's next earnings date?

Based on SEC filing cadence, Abbott Laboratories (ABT)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ABT stock expected to move on earnings?

Volatility modeling currently projects a ±5.5% event move for ABT, spanning a range between $100.36 and $112.04.

Direct Sub-Reports: ABT RQD Cockpit ABT 12M Forecast ABT Earnings & Move ABT Dividends & DRIP ABT Insiders & 13F ABT Whale Options ABT Profit Sankey ABT News & Why
ROARABLE RATING BRIEF • RQD 77/100 (B+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ABT — Abbott Laboratories: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:09:10Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ABT scores 77 out of 100 with a letter grade of B+, labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are: Fundamental Cash Engine 16/20 (ROIC 11.9%; FCF yield 4.09%), Whale 13F Flow 15/20 (institutional accumulation and options positioning), Insider Conviction 14/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 16/20 (beta 0.99; sector sensitivity), and Forensic Balance Sheet 16/20 (Altman Z 4.36; Piotroski F 8/9; Debt/Equity 0.19).

For a prospective investor, the strongest support comes from the cash engine and balance sheet pillars, which both sit at 16/20, alongside a beta near 1.0 that indicates market-like volatility relative to the broader market. The weakest pillar is Insider Conviction at 14/20, meaning insider and congressional flow is supportive but less decisive than the operating and balance sheet evidence. Valuation is the principal tradeoff: the stock trades at a trailing P/E of 27.7 and EV/EBITDA of 18.4, so upside depends on sustaining earnings growth rather than on a low entry multiple. The rating is a quantitative summary of the provided data and is not a recommendation to act.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$104.57$180.95B27.725.818.43.772.27%0.99$81.97 - $132.0311.9%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$44328.0M$8053.0M$6524.0MN/A$7395.0M$8522.0M$9896.0M
FY 2024$41950.0M$6825.0M$13402.0MN/A$6351.0M$7616.0M$12625.0M
FY 2023$40109.0M$6478.0M$5723.0MN/A$5456.1MN/A$23287.8M

Per the market data, gross margin is 56.4%, operating margin 18.2%, and net margin 14.7%, with ROIC of 11.9% and FCF yield of 4.09%. Per the Roarable RQD rating, the Altman Z-Score is 4.36 and the Piotroski F-Score is 8/9, with Debt/Equity at 0.19. Reported debt declined from $23287.8M (FY 2023) to $9896.0M (FY 2025) while cash rose to $8522.0M, and FY 2024 net income ($13402.0M) exceeds its operating income ($6825.0M), a divergence the source data does not explain.

Open Questions

  • What is the heart failure news referenced in the Yahoo Finance headline, and what valuation impact does the source attribute to it?
  • What is the scope and timing of the spinoff referenced in the Investor's Business Daily coverage?
  • What drove the divergence between FY 2024 net income ($13402.0M) and operating income ($6825.0M), and is it recurring?
  • Why do EPS figures show N/A across all reported periods when trailing EPS is listed at 3.77?
  • Which specific institutional, insider, and congressional transactions underpin the RQD pillar scores of 15/20 and 14/20?

ABT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Abbott Laboratories (ABT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABT Bull vs. Bear Conversation Board — What's Your Call at $106.20?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ABT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $123.39 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ABT (B+ • RQD 77/100) a Buy at $104.57?

Welcome to the ABT (Abbott Laboratories) Roar Pit. Current RQD Composite is 77/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $82.61 (-21.0%)
Spot @ $104.57

Pump the brakes on ABT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ABT, but look at what you are paying: 27.7x trailing P/E with 56.4% gross margins. Unless Abbott Laboratories expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $129.67 (+24.0%)
Spot @ $104.57

ABT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ABT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $104.57 (52-wk range $81.97 - $132.03), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%